亚砷酸注射液应用于急性早幼粒细胞白血病治疗的历程  

History of Application of Arsenious Acid Injection in the Treatment of Acute Promyelocytic Leukemia

作　　者：白云龙[1] 单宏丽[1] 周晋[2] BAI Yunlong;SHAN Hongli;ZHOU Jin(School of Pharmacy,Harbin Medical University,Harbin 150081;First Clinical Medical College Affiliated to Harbin Medical University)

机构地区：[1]哈尔滨医科大学药学院 [2]哈尔滨医科大学附属第一临床医学院

出　　处：《中医杂志》2019年第1期28-30,共3页Journal of Traditional Chinese Medicine

摘　　要：20世纪70年代开始,哈尔滨医科大学附属第一医院张亭栋团队经过充分研究,将亚砷酸(三氧化二砷)为主要成分的癌灵注射液应用于白血病患者的治疗,发现其尤其适用于急性早幼粒细胞白血病。鉴于其存在的副作用,又于1995年开始,联合上海瑞金医院陈竺教授开展了三氧化二砷毒性反应发生机制研究。根据研究结果创立了亚砷酸持续缓慢静脉输注法,基本解决了砷剂治疗急性早幼粒细胞性白血病中的高白细胞血症和长QT间期综合征等临床医学中的疑难问题。该系列研究极大地提高了急性早幼粒细胞白血病的临床疗效与安全性。Since the 1970 s,the team of ZHANG Tingdong of the First Affiliated Hospital of Harbin Medical University has fully studied the application of Ailing Injection(癌灵注射液)with the main component of arsenic trioxide in the treatment of leukemia patients,and found that it is especially suitable for acute promyelocytic leukemia.In view of its side effects,they conducted research on the mechanism of arsenic trioxide toxicity together with Professor CHEN Zhu from Shanghai Ruijin Hospital in 1995.According to the research results,the continuous slow intravenous infusion of arsenic acid was established,which basically solved the difficult problems in the clinical medicine such as hyperleukocytosis and long QT syndrome in arsenic treatment of acute promyelocytic leukemia.This series of studies have greatly improved the clinical efficacy and safety of acute promyelocytic leukemia.

关 键 词：白血病 急性早幼粒细胞白血病 三氧化二砷 亚砷酸注射液 持续缓慢静脉输注法 

分 类 号：R733.71[医药卫生—肿瘤]